Drugs / CEVIPABULIN
CEVIPABULIN
also known as
TTI-237 · CEVIPABULIN FUMARATE · CEVIPABULIN SUCCINATE · Cevipabulina · Cevipabuline · TTI-237 FUMARATE DIHYDRATE · TTI-237 SUCCINATE DIHYDRATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00195325 | Aug 2005 → ? | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00195247 | May 2005 → ? | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEVIPABULIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | CEVIPABULIN FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | CEVIPABULIN SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | Cevipabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | Cevipabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | TTI-237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00195247 ↗ |
| Known as | TTI-237 FUMARATE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Known as | TTI-237 SUCCINATE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1182714 ↗ |
| Modality | Small molecule | — CHEMBL1182714 ↗ |
| Route | Intravenous | “TTI-237 Administered Intravenously Every 3 Weeks” NCT00195247 ↗ |